Basit öğe kaydını göster

Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.

dc.contributor.authorSpelman, T.
dc.contributor.authorHarvrdova, E. K.
dc.contributor.authorHorakova, D.
dc.contributor.authorIzquierdo, G.
dc.contributor.authorKalincik, T.
dc.contributor.authorLugaresi, A.
dc.contributor.authorMcCombe, P.
dc.date.accessioned2020-06-21T13:06:36Z
dc.date.available2020-06-21T13:06:36Z
dc.date.issued2018
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.urihttps://hdl.handle.net/20.500.12712/11387
dc.description34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -- OCT 10-12, 2018 -- Berlin, GERMANYen_US
dc.descriptionMcCombe, Pamela/0000-0003-2704-8517; Lugaresi, Alessandra/0000-0003-2902-5589;en_US
dc.descriptionWOS: 000446861400033en_US
dc.description.abstract…en_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosisen_US
dc.description.sponsorshipCzech Ministry of EducationMinistry of Education, Youth & Sports - Czech Republic [Q27/LF1]; BiogenBiogen; Charles University in Prague [PRVOUK-P26/LF1/4]; Czech Minsitry of Education [PROGRESQ27/LF1]; Czech Ministry of HealthMinistry of Health, Czech Republic [NT13237-4/2012]; RocheRoche Holding; BayerBayer AG; MerckMerck & Company; NovartisNovartis; SanofiSanofi-Aventis; Teva; Fondazione Italiana Sclerosi Multipla (FISM)Fondazione Italiana Sclerosi Multipla (FISM); CIHRCanadian Institutes of Health Research (CIHR); MS Society of Canada; GenzymeGenzyme Corporation; Teva-Neuroscience; Teva Neurosciences; Mitsubishi; ONO Pharmaceuticals; Sanofi-AventisSanofi-Aventis; Almirall; Biogen IdecBiogen; Sanofi Genzyme; Bayer ScheringBayer AG; Novartis Pharma; NHMRC AustraliaNational Health and Medical Research Council of Australia; MS Research Australia; UK MS Trusten_US
dc.description.sponsorshipEva Kubala Havrdova received speaker honoraria and consultant fees from Actelion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi and Teva, and support for research activities from Czech Ministry of Education [project Progres Q27/LF1].; Dana Horakova received speaker honoraria and consulting fees from Biogen, Merck, Teva and Novartis, as well as support for research activities from Biogen and research grants from Charles University in Prague [PRVOUK-P26/LF1/4], Czech Minsitry of Education [PROGRESQ27/LF1] and Czech Ministry of Health [NT13237-4/2012].; Alessandra Lugaresi is a Bayer, Biogen, Genzyme, Merck Advisory Board Member. She received travel grants and honoraria from Roche, Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institution received research grants from Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM).; Pierre Duquette served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme.; Pierre Grammond is a Merck, Novartis, Teva-neuroscience, Biogen and Genzyme advisory board member, consultant for Merck, received payments for lectures by Merck, Teva-Neuroscience and Canadian Multiple sclerosis society, and received grants for travel from Teva-Neuroscience and Novartis.; Francois Grand'Maison received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals.; Franco Granella received research grant from Biogen, served on scientific advisory boards for Biogen, Novartis, Merck, and Sanofi-Aventis and received funding for travel and speaker honoraria from Biogen, Merck, Sanofi-Aventis, and Almirall.; Patrizia Sola served on scientific advisory boards for Biogen Idec and TEVA, she has received funding for travel and speaker honoraria from Biogen Idec, Merck, Teva, Sanofi Genzyme, Novartis and Bayer and research grants for her Institution from Bayer, Biogen, Merck, Novartis, Sanofi, Teva.; Vincent Van Pesch has received travel grants from Biogen, Bayer Schering, Genzyme, Merck, Teva, Roche and Novartis Pharma. His institution receives honoraria for consultancy and lectures from Biogen, Bayer Schering, Genzyme, Merck, Roche, Teva and Novartis Pharma as well as research grants from Novartis Pharma, Roche and Bayer Schering.; Helmut Butzkueven received compensation for steering committee, advisory board and consultancy fees from Biogen, Merck, Roche, Novartis, Teva, Oxford Pharamgenesis; research support from Novartis, Biogen, Merck, NHMRC Australia, MS Research Australia, UK MS Trust.en_US
dc.language.isoengen_US
dc.publisherSage Publications Ltden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleComparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.en_US
dc.typeconferenceObjecten_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume24en_US
dc.identifier.startpage25en_US
dc.identifier.endpage26en_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster